This podcast discusses the noteworthy outcomes of MAPS Clinical Trials, revealing a significant success rate where 71% of participants no longer qualify for PTSD after undergoing MDMA-Assisted Therapy. This statistic underscores the potential efficacy of the treatment and its transformative impact on individuals struggling with post-traumatic stress disorder.

It highlights HB's strategic approach to scaling MDMA-Assisted Therapy, shedding light on the organization's efforts to make this innovative treatment more widely accessible for Veterans dealing with PTSD.

Listen to the podcast episode.